Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$238.21 USD
+1.04 (0.44%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $238.25 +0.04 (0.02%) 6:28 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.21 USD
+1.04 (0.44%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $238.25 +0.04 (0.02%) 6:28 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Zacks Industry Outlook Highlights Becton, Dickinson and Company, Patterson Companies and SmileDirectClub
by Zacks Equity Research
Becton, Dickinson and Company, Patterson Companies and SmileDirectClub are part of Zacks Industry Outlook article.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.
3 Dental Supplies Stocks to Buy Amid Industry Headwinds
by Zacks Equity Research
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, PDCO and SDC.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BDX or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
Earnings Season Scorecard and Fresh Analyst Research Reports for Chevron, Adobe & AMD
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Chevron (CVX), Adobe (ADBE), AMD (AMD) and 16 other stocks.
3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
BDX vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
BD's (BDX) Latest Collaboration to Enhance Patient Care
by Zacks Equity Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
Why Is Dentsply (XRAY) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox
by Zacks Equity Research
BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
by Zacks Equity Research
BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.
BD's (BDX) Latest Product to Transform Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.
New Strong Sell Stocks for May 25th
by Zacks Equity Research
ALGN, AUD, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2022.
BD (BDX) Introduces New Molecular Diagnostic Platform in US
by Zacks Equity Research
BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
by Zacks Equity Research
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
New Strong Sell Stocks for May 13th
by Zacks Equity Research
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
Company News for May 6, 2022
by Zacks Equity Research
Companies In The News Are: SHOP, WRK, BDX, ALB.
BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.
Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?